Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences
Provided By GlobeNewswire
Last update: Jun 25, 2025
Amneal holds exclusive U.S. commercialization rights; BLA filing expected in Q4 2025
Poised to be among the first wave of biosimilars in the $3.9 billion U.S. omalizumab market and an important growth driver for Amneal
Read more at globenewswire.com
